Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 784 | 44% |
| 2020 | 9 | 678 | 47% |
| 2021 | 9 | 763 | 51% |
| 2022 | 9 | 808 | 54% |
| 2023 | 8 | 843 | 57% |
| 2024 | 6 | 772 | 59% |
| 2025 from claims | – | 840 679–986 | 59% |
| 2026 forecast | – | 872 683–1,095 | 60% |
| 2027 forecast | – | 905 671–1,196 | 60% |
| 2028 forecast | – | 939 665–1,296 | 61% |
| 2029 forecast | – | 974 662–1,396 | 61% |
| 2030 forecast | – | 1,010 661–1,498 | 62% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Texas; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 3 | 795+1.4%/yr | +1.4%/yr | 0.4 | 0% | 1,250 in 2030+7.8%/yr |
| Georgia | 2 | 335+1.7%/yr | +1.7%/yr | 0.4 | 0% | 260 in 2030−3.9%/yr |
| North Carolina | 3 | 334−1.9%/yr | −1.9%/yr | 0.3 | 0% | 320 in 2030−0.8%/yr |
| Virginia | 1 | 278+2.6%/yr | +2.6%/yr | 0.3 | 0% | 470 in 2030+9%/yr |
| Maryland | 5 | 276+7%/yr | +7%/yr | 0.3 | 0% | 670 in 2030+16%/yr |
| South Carolina | 2 | 220−0.1%/yr | −0.1%/yr | 0.3 | 0% | 260 in 2030+3.1%/yr |
| Tennessee | 3 | 213+0.5%/yr | +0.5%/yr | 0.3 | 0% | 280 in 2030+4.6%/yr |
| Louisiana | 0 | 112+4%/yr | +4%/yr | 0.3 | 0% | 290 in 2030+17%/yr |
| Alabama | 0 | 110+2.3%/yr | +2.3%/yr | 0.3 | 0% | 140 in 2030+4.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 203 | 11,818−2.4%/yr | −2.4%/yr | 5.90.8× | 24% | 13,700 in 2030+2.5%/yr |
| Tumor & fibroid embolization | 20 | 1,239+2.9%/yr | +2.9%/yr | 0.61.0× | 63% | 3,140 in 2030+17%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Exact Sciences leads with 34% of company spending on these surgeons in 2025, +12 pts on 2024.
In 2025, 21 companies reported engagement with Texas’s surgeons worth $776K in consulting, speaking, meals and travel tied to these products, about $129K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.